Technology | Contrast Media | October 04, 2016

GE Healthcare Announces FDA Labeling Change for Optison Ultrasound Contrast Agent

Administration has removed contraindication for use in patients with cardiac shunts and for administration by intra-arterial injection

GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection

October 4, 2016 — GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound contrast agent Optison (Perflutren protein-Type A Microspheres Injectable Suspension, USP). The FDA removed the contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection. Both contraindications have been revised and moved to the WARNINGS AND PRECAUTIONS section (5.3 : Systemic Embolization) of the Full Prescribing Information.

Optison is the first contrast agent available in the United States to receive this contraindication label change.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal flow of the circulatory system. Previously, in suspected cardiac shunt populations, an agitated saline procedure was needed to determine if a shunt existed and whether the patient was contraindicated to receive an ultrasound contrast agent.

Sharon L. Mulvagh, M.D., professor of medicine, Women's Heart Clinic director, associate director, preventive cardiology consultant in cardiovascular diseases, Mayo Clinic and Mayo Clinic College of Medicine, said: "I am very pleased that the FDA has approved the removal of the cardiac shunt contraindication from the ultrasound contrast agent Optison. This label change will allow more patients access to a diagnostic imaging tool that has established safety and efficacy. The FDA’s decision to remove this contraindication is supported by a body of data from studies demonstrating safety and clinical benefits of all ultrasound contrast agents in patients with cardiovascular diseases.”

She added: “This is an important step forward in eliminating barriers to ultrasound contrast use and delivering quality diagnostic care of value to our patients.”

Steven Feinstein, M.D., co-president of the International Contrast Ultrasound Society, said: “Up to one-third of our patients have known or suspected cardiac shunts and, thanks to this important FDA decision, they too will now have access to ultrasound contrast agents, which offer an inexpensive and radiation-free option for diagnostic imaging. The International Contrast Ultrasound Society applauds the FDA for its decision, and believes it will benefit individual patients as well as our healthcare delivery system.”

Jonathan Lindner, M.D., M. Lowell Edwards Professor of Cardiology at the Knight Cardiovascular Center, Oregon Health & Science University, said: “Thanks to the overwhelming weight of evidence from clinical trials, most practitioners in the field of echocardiography already realize the benefits of using contrast agents and understand their capacity to improve diagnostic accuracy, improve outcomes and streamline care. However, a major obstacle to widespread use has been lack of consensus and confusion regarding how far one needs to go to exclude shunts, no matter how small. The decision by the FDA removes a barrier to using this contrast agent, and may result in an increase in the number of labs that will choose to utilize this important technology, which allows clinicians to provide the best care possible.”

For more information: www.gehealthcare.com

Related Content

Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
News | Ultrasound Imaging | May 15, 2017
Soundwaves LLC recently announced the diversification of its portable ultrasound services beyond obstetrics and...
radiologist reading ultrasound

Photo courtesy of Fujifilm

News | Clinical Study | May 11, 2017
According to new research by the Harvey L. Neiman Health Policy Institute, the use of follow-up imaging is...
Philips Introduces New OB/GYN Ultrasound Innovations for Epiq and Affiniti Systems
News | Ultrasound Womens Healthcare | May 10, 2017
Philips announced the debut of its TrueVue, GlassVue and aRevealA.I. capabilities on the company’s Epiq 7 and 5 and...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
News | Cardio-oncology | May 03, 2017
Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (...
Clarius Demonstrates Point-of-Care Ultrasound for Disaster and Emergency Medicine
News | Ultrasound Imaging | April 25, 2017
Clarius Mobile Health will demonstrate its wireless, handheld ultrasound scanners at the World Association for Disaster...
GE Healthcare and Echosens Introduce Integrated Liver Package for Logiq S8 XDclear 2.0 Ultrasound
News | Ultrasound Imaging | April 19, 2017
To further support clinicians in their fight against chronic liver disease, Echosens and GE Healthcare have joined...
Cardiovascular Institute of the South Upgrades Cardiac Ultrasound With New Toshiba Medical Systems
News | Cardiovascular Ultrasound | April 17, 2017
April 17, 2017 — To bolster its technology and treatment capabilities for coronary and peripheral artery diseases acr
Overlay Init